Home  |  Contact

Cellosaurus T24rCDDP1000 (CVCL_RR21)

[Text version]

Cell line name T24rCDDP1000
Accession CVCL_RR21
Resource Identification Initiative To cite this cell line use: T24rCDDP1000 (RRID:CVCL_RR21)
Comments Part of: Resistant Cancer Cell Line (RCCL) collection.
Population: Caucasian; Swedish.
Doubling time: 24.7 hours (PubMed=26055179).
Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
Derived from sampling site: Urinary bladder.
Sequence variations Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line).
Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line).
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0554 (T24)
Sex of cell Female
Age at sampling 82Y
Category Cancer cell line
Web pages http://www.wass-michaelislab.org/rccl.php
Publications

PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002
Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M., Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.
Transl. Oncol. 8:210-216(2015)

Cross-references
Other Wikidata; Q54971462
Entry history
Entry creation05-Mar-2018
Last entry update20-May-2021
Version number8